50th Orphan Medicine Receives Positive Opinion
The European Union's efforts in combating rare diseases reached a new milestone this October, with the 50th positive opinion on an 'orphan' medicine being adopted by the EMEA's Committee for Medicinal Products for Human Use (CHMP).
50th orphan medicine receives positive opinion
The European Union's efforts in combating rare diseases reached a new milestone this October, with the 50th positive opinion on an 'orphan' medicine being adopted by the EMEA's Committee for Medicinal Products for Human Use (CHMP).
To date, a total of 569 medicines have been awarded orphan-designation status by the European Commission, based on recommendations of the
EMEA's Committee for Orphan Medicinal Products (COMP). Of these, 50 have now been successful in obtaining a positive EMEA opinion on marketing authorisation, with many more positive opinions expected over the coming years.
Developed specifically for the diagnosis, treatment or prevention of rare diseases, these medicines have the potential to offer relief to many thousands of European citizens suffering from chronic and often debilitating diseases who would otherwise have few-if any-treatment options available.
A listing of the 50 orphan medicines to have received a positive CHMP opinion is available here:
http://www.emea.europa.eu/pdfs/human/comp/56357508en.pdf
See also: Orphan drugs and rare diseases at a glance
http://www.emea.europa.eu/pdfs/human/comp/29007207en.pdf
EMEA website section: Orphan medicinal products
http://www.emea.europa.eu/htms/human/orphans/intro.htm
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Expands Farapulse PFA Approval to Persistent AF After Strong ADVANTAGE AF Trial Results
July 7th 2025Boston Scientific’s Farapulse Pulsed Field Ablation System is now approved for treating persistent atrial fibrillation, following 12-month data from the ADVANTAGE AF trial showing strong safety, high freedom from AF, and no major complications.
